The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Avedisova A.S.

Serbsky Federal Medical Research Centre for Psychiatry and Narcology;
Soloviev Scientific and Practical Center of Psychoneurology

Guekht A.B.

Serbsky Federal Medical Research Centre for Psychiatry and Narcology;
Soloviev Scientific and Practical Center of Psychoneurology

Zakharova K.V.

Serbsky Federal Medical Research Centre for Psychiatry and Narcology;
Soloviev Scientific and Practical Center of Psychoneurology

Akzhigitov R.G.

Serbsky Federal Medical Research Centre for Psychiatry and Narcology;
Soloviev Scientific and Practical Center of Psychoneurology

The efficacy of pharmacological approaches to therapy of the apathy syndrome in dementia disorders (the review)

Authors:

Avedisova A.S., Guekht A.B., Zakharova K.V., Akzhigitov R.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(4): 126‑133

DOI: 10.17116/jnevro201811841126-133

Read: 1010 times

Download PDF (RU)
Contact the author
Table of contents

THE EFFICACY OF PHARMACOLOGICAL APPROACHES TO THERAPY OF THE APATHY SYNDROME IN DEMENTIA DISORDERS (THE REVIEW)
THE EFFICACY OF PHARMACOLOGICAL APPROACHES TO THERAPY OF THE APATHY SYNDROME IN DEMENTIA DISORDERS (THE REVIEW)

To cite this article:

Avedisova AS, Guekht AB, Zakharova KV, Akzhigitov RG. The efficacy of pharmacological approaches to therapy of the apathy syndrome in dementia disorders (the review). S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(4):126‑133. (In Russ.)
https://doi.org/10.17116/jnevro201811841126-133

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10
Treatment of acute postoperative pain and prevention of chro­nic postoperative pain syndrome. Piro­gov Russian Journal of Surgery. 2024;(12):81-86
Diseases of the upper gastrointestinal tract in pregnancy: what should the gastroenterologist consider?. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):30-42
Abstract:

The article presents a literature review of psychopharmacological methods of treatment of the apathy syndrome, which is common in neurocognitive disorders. The review provides recommendations for the management of such patients, taking into account evidence-based medicine.

Keywords:

apathy
neurocognition
pharmacotherapy

Authors:

Avedisova A.S.

Serbsky Federal Medical Research Centre for Psychiatry and Narcology;
Soloviev Scientific and Practical Center of Psychoneurology

Guekht A.B.

Serbsky Federal Medical Research Centre for Psychiatry and Narcology;
Soloviev Scientific and Practical Center of Psychoneurology

Zakharova K.V.

Serbsky Federal Medical Research Centre for Psychiatry and Narcology;
Soloviev Scientific and Practical Center of Psychoneurology

Akzhigitov R.G.

Serbsky Federal Medical Research Centre for Psychiatry and Narcology;
Soloviev Scientific and Practical Center of Psychoneurology

Close metadata

References:

  1. Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer’s disease. J Am Geriatr Soc. 2001;49(12):1700-1707. Review. PubMed PMID: 11844006.
  2. Avedisova AS, Guekht AB, Zakharova KV, Dashkina GK, Popov GR. Apathy in the structure of mental and neurological disorders of the old age. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2014;114(6):77-85. Review. (In Russ.). PubMed PMID: 25075419. (In Russ.)
  3. Pluck GC, Brown RG. Apathy in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2002;73:636-642. https://doi.org/10.1136/jnnp.73.6.636
  4. Brown RG, Pluck G. Negative symptoms: the «pathology» of motivation and goal-directed behaviour. Trends in Neurosciences [Internet]. Elsevier BV. 2000;23(9):412-417. https://doi.org/10.1016/s0166-2236(00)01626-x
  5. Differential diagnosis and classification of apathy. American Journal of Psychiatry [Internet]. American Psychiatric Publishing. 1990;147(1):22-30. https://doi.org/10.1176/ajp.147.1.22
  6. Levy R, Czernecki V. Apathy and the basal ganglia. Journal of Neurology [Internet]. Springer Nature. 2006;253(7):54-61. https://doi.org/10.1007/s00415-006-7012-5
  7. Robert P, Onyike CU, Leentjens AF, Dujardin K, Aalten P, Starkstein S, Verhey FR, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M, Boyer P, Lorca PM, Thibaut F, Gauthier S, Grossberg G, Vellas B, Byrne J. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry. 2009;24(2):98-104. https://doi.org/10.1016/j.eurpsy.2008.09.001
  8. Derouesné C. Apathy: a useful but limited concept. Psychol Neuropsychiatr Vieil. 2004;2(1):19-28. Review. French. PubMed PMID: 15683965.
  9. Diesfeldt HFA, Houte LR, Moerkens RM. Duration of survival in senile dementia. Acta Psychiatrica Scandinavica [Internet]. Wiley-Blackwell; 1986;73(4):366-371. https://doi.org/10.1111/j.1600-0447.1986.tb02697.x
  10. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology. 2001;56(6):730-736. https://doi.org/10.1212/WNL.56.6.730
  11. Crocco EA, Loewenstein DA. Psychiatric aspects of mild cognitive impairment. Current Psychiatry Reports [Internet]. Springer Nature. 2005;7(1):32-36. https://doi.org/10.1007/s11920-005-0021-8
  12. Berman K, Brodaty H, Withall A, Seeher K. Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatry. 2012;20(2):104-122. https://doi.org/10.1097/JGP.0b013e31822001a6
  13. Vink AC, Birks JS, Bruinsma MS, Scholten RJ. Music therapy for people with dementia. Cochrane Database Syst Rev. 2004;(3):003477. Review. PubMed PMID: 15266489.
  14. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51(12):1235-1241. PubMed PMID: 10086815.
  15. Reliability of the PEDro Scale for Rating Quality of Randomized Controlled Trials. Physical Therapy [Internet]. Oxford University Press (OUP). 2003. https://doi.org/10.1093/ptj/83.8.713
  16. NHMRC NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. Available at www.nhmrc.gov.au/guidelines/publications
  17. O’Brien P, Silagy C, McCallum J. How to Review the Evidence: Systematic Identification and Review of the Scientific Literature. Spine. 1999;24:1813-1819.
  18. Rea R, Carotenuto A, Fasanaro AM, Traini E, Amenta F. Apathy in Alzheimer’s disease: any effective treatment? Scientific World Journal. 2014:421385. https://doi.org/10.1155/2014/421385
  19. Götestam KG, Ljunghall S, Olsson B. A double-blind comparison of the effects of haloperidol and cis(Z)-clopenthixol in senile dementia. Acta Psychiatrica Scandinavica [Internet]. Wiley-Blackwell. 1981;64:46-53. https://doi.org/10.1111/j.1600-0447.1981.tb06213.x
  20. Devanand DP, Sackeim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer’s disease. Arch Neurol. 1989;46(8):854-857. https://doi.org/10.1001/archneur.1989.00520440036018
  21. Burgio LD, Sinnott J, Janosky JE, Hohman MJ. Physicians’ acceptance of behavioral treatments and pharmacotherapy for behavioral disturbances in older adults. Gerontologist. 1992;32(4):546-551. https://doi.org/10.1093/geront/32.4.546
  22. Barnes R, Veith R, Okimoto J, Raskind M, Gumbrecht G. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry. 1982;139(9):1170-1174. https://doi.org/10.1176/ajp.139.9.1170
  23. Kirven LE, Montero EF. Comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility: double-blind study. J Am Geriatr Soc. 1973;21(12):546-551. https://doi.org/10.1111/j.1532-5415.1973.tb01661.x
  24. Barton R, Hurst L. Unnecessary use of tranquilizers in elderly patients. Br J Psychiatry. 1966;112(491):989-990. https://doi.org/10.1192/bjp.112.491.989
  25. Birkett DP, Boltuch B. Chlorpromazine in geriatric psychiatry. J Am Geriatr Soc. 1972;20(8):403-406. https://doi.org/10.1111/j.1532-5415.1972.tb01644.x
  26. Cahn LA, Diesfeldt HF. The use of neuroleptics in the treatment of dementia in old age. A critical analysis with reference to an experiment with a long-acting oral neuroleptic (penfluridol Janssen). Psychiatr Neurol Neurochir. 1973;76(6):411-420.
  27. Goldstein SE. The use of mesoridazine in geriatrics. Curr Ther Res Clin Exp. 1974;16(4):316-323.
  28. Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of Citalopram, Perphenazine, and Placebo for the Acute Treatment of Psychosis and Behavioral Disturbances in Hospitalized, Demented Patients. American Journal of Psychiatry [Internet]. American Psychiatric Publishing. 2002;159(3):460-465. https://doi.org/10.1176/appi.ajp.159.3.460
  29. Tobin JM, Brousseau ER, Lorenz AA. Clinical evaluation of haloperidol in geriatric patients. Geriatrics. 1970;25(6):119-122.
  30. Petrie WM, Ban TA, Berney S, Fujimori M, Guy W, Ragheb M, et al. Loxapine in Psychogeriatrics. Journal of Clinical Psychopharmacology [Internet]. Ovid Technologies (Wolters Kluwer Health). 1982;2(2):122-125. https://doi.org/10.1097/00004714-198204000-00008
  31. Birkett D, Raskin A. Arteriosclerosis, Infarcts, and Dementia. Journal of the American Geriatrics Society [Internet]. Wiley-Blackwell. 1982;30(4):261-266. https://doi.org/10.1111/j.1532-5415.1982.tb07099.x
  32. Lovett WC, Stokes DK, Taylor LB, Young ML, Free SM, Phelan DG. Management of behavioral symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol. J Clin Psychiatry. 1987;48(6):234-236.
  33. Oberholzer AF, Hendriksen C, Monsch AU, Heierli B, Sthelin HB. Safety and Effectiveness of Low-Dose Clozapine in Psychogeriatric Patients: A Preliminary Study. International Psychogeriatrics [Internet]. Cambridge University Press (CUP); 1992;4(2):187-195. https://doi.org/10.1017/s1041610292001017
  34. Onor ML, Saina M, Trevisiol M, Cristante T, Aguglia E. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia. Progress in Neuro-Psychopharmacology and Biological Psychiatry [Internet]. Elsevier BV. 2007;31(1):205-209. https://doi.org/10.1016/j.pnpbp.2006.09.001
  35. Negron AE, Reichman WE. Risperidone in the Treatment of Patients With Alzheimers Disease With Negative Symptoms. International Psychogeriatrics [Internet]. Cambridge University Press (CUP); 2000;12(4):527-536. https://doi.org/10.1017/s1041610200006633
  36. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19(2):115-126. https://doi.org/10.1002/gps.1032
  37. Monga V, Padala PR. Aripiprazole for Treatment of Apathy. Innov Clin Neurosci. 2015;12(9-10):33-36. PubMed PMID: 26634180; PubMed Central PMCID: PMC4655898.
  38. Withall A, Brodaty H, Altendorf A, Sachdev PS. A longitudinal study examining the independence of apathy and depression after stroke: the Sydney Stroke Study. International Psychogeriatrics [Internet]. Cambridge University Press (CUP). 2010;23(02):264-273. https://doi.org/10.1017/s1041610209991116
  39. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatrica Scandinavica [Internet]. Wiley-Blackwell. 1992;86(2):138-145. https://doi.org/10.1111/j.1600-0447.1992.tb03242.x
  40. Siddique H, Hynan LS, Weiner MF. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer’s disease. J Clin Psychiatry. 2009;70(6):915-918. https://doi.org/10.4088/JCP.08m04828
  41. Lebert F, Pasquier F. Trazodone in the treatment of behaviour in frontotemporal dementia. Hum Psychopharmacol Clin Exp. 1999;14:27-281.
  42. Lebert F, Delacourte A, Pasquier F. Treatment of frontotemporal dementia. Alzheimer’s Disease and Related Disorders Annual — 2002 [Internet]. Informa UK Limited. 2002;171-182. https://doi.org/10.1201/b14342-12
  43. Lawlor BA, Sunderland T, Mellow AM, Hill JL, Newhouse PA, Murphy DL. A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects. Biological Psychiatry [Internet]. Elsevier BV. 1989;25(6):679-686. https://doi.org/10.1016/0006-3223(89)90237-0
  44. Adler G, Teufel M, Drach LM. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. International Journal of Geriatric Psychiatry [Internet]. Wiley-Blackwell. 2003;18(7):653-655. https://doi.org/10.1002/gps.894
  45. Ikeda M, Shigenobu K, Fukuhara R, Hokoishi K, Maki N, Nebu A, et al. Efficacy of Fluvoxamine as a Treatment for Behavioral Symptoms in Frontotemporal Lobar Degeneration Patients. Dementia and Geriatric Cognitive Disorders [Internet]. S. Karger AG. 2004;17(3):117-121. https://doi.org/10.1159/000076343
  46. Zahodne LB, Bernal-Pacheco O, Bowers D, Ward H, Oyama G, Limotai N, et al. Are Selective Serotonin Reuptake Inhibitors Associated With Greater Apathy in Parkinson’s Disease? The Journal of Neuropsychiatry and Clinical Neurosciences [Internet]. American Psychiatric Publishing. 2012;24(3):326-330. https://doi.org/10.1176/appi.neuropsych.11090210
  47. Sansone RA, Sansone LA. SSRI-Induced Indifference. Psychiatry (Edgmont). 2010;7(10):14-18. PubMed PMID: 21103140.
  48. Bolling MY, Kohlenberg RJ. Reasons for Quitting Serotonin Reuptake Inhibitor Therapy: Paradoxical Psychological Side Effects and Patient Satisfaction. Psychotherapy and Psychosomatics [Internet]. S. Karger AG. 2004;73(6):380-385. https://doi.org/10.1159/000080392
  49. Reinblatt SP, Riddle MA. Selective Serotonin Reuptake Inhibitor-Induced Apathy: A Pediatric Case Series. Journal of Child and Adolescent Psychopharmacology [Internet]. Mary Ann Liebert Inc. 2006;16(1-2):227-233. https://doi.org/10.1089/cap.2006.16.227
  50. Callegari I, Mattei C, Benassi F, Krueger F, Grafman J, Yaldizli Ö, et al. Agomelatine Improves Apathy in Frontotemporal Dementia. Neurodegenerative Diseases [Internet]. S. Karger AG. 2016;16(5-6):352-356. https://doi.org/10.1159/000445873
  51. Cummings JL, McRae T, Zhang R. Effects of Donepezil on Neuropsychiatric Symptoms in Patients With Dementia and Severe Behavioral Disorders. The American Journal of Geriatric Psychiatry [Internet]. Elsevier BV. 2006;14(7):605-612. https://doi.org/10.1097/01.jgp.0000221293.91312.d3
  52. Robert P. Understanding and managing behavioural symptoms in Alzheimer’s Disease and related dementias: focus on rivastigmine. Curr Med Res Opin. 2002;18(3):156-171. https://doi.org/10.1185/030079902125000561
  53. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer’s disease: the cholinergic hypothesis revisited. Neurology. 1996;47(4):876-883. https://doi.org/10.1212/WNL.47.4.876
  54. Kaufer DI. Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders. Current Psychiatry Reports [Internet]. Springer Nature. 1999;1(1):78-84. https://doi.org/10.1007/s11920-999-0013-1
  55. Overshott R, Byrne J, Burns A. Nonpharmacological and pharmacological interventions for symptoms in Alzheimer’s disease. Expert Review of Neurotherapeutics [Internet]. Informa Healthcare. 2004;4(5):809-821. https://doi.org/10.1586/14737175.4.5.809
  56. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open-label study. J Geriatr Psychiatry Neurol. 1996;9(1):1-6. https://doi.org/10.1177/089198879600900101
  57. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590-1599. https://doi.org/10.1111/j.1532-5415.2001.49266.x
  58. Seltzer B. Efficacy of Donepezil in Early-Stage Alzheimer Disease. Archives of Neurology [Internet]. American Medical Association (AMA). 2004;61(12):1852. https://doi.org/10.1001/archneur.61.12.1852
  59. Mega MS, Masterman DM, O’Connor SM, Barclay TR, Cummings JL. The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease. Archives of Neurology [Internet]. American Medical Association (AMA). 1999;56(11):1388. https://doi.org/10.1001/archneur.56.11.1388
  60. Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetlik DA. Effects of donepezil on emotional/behavioral symptoms in Alzheimer’s disease patients. J Clin Psychiatry. 2000;61(7):487-492. https://doi.org/10.4088/jcp.v61n0705
  61. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2001;57(4):613-620. https://doi.org/10.1212/wnl.57.4.613
  62. Tanaka M, Namiki C, Thuy DH, Yoshida H, Kawasaki K, Hashikawa K, Fukuyama H, Kita T. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer’s disease. J Neurol Sci. 2004;225(1-2):135-141. https://doi.org/10.1016/j.jns.2004.07.009
  63. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology [Internet]. Ovid Technologies (Wolters Kluwer Health). 2004;63(2):214-219. https://doi.org/10.1212/01.wnl.0000129990.32253.7b
  64. Rockwood K, Fay S, Gorman M, Carver D, Graham JE. The clinical meaningfulness of ADAS-Cog changes in Alzheimer’s disease patients treated with donepezil in an open-label trial. BMC Neurol. 2007;7:26. https://doi.org/10.1186/1471-2377-7-26
  65. Lopez OL, Mackell JA, Sun Y, Kassalow LM, Xu Y, McRae T, Li H. Effectiveness and safety of donepezil in Hispanic patients with Alzheimer’s disease: a 12-week open-label study. J Natl Med Assoc. 2008;100(11):1350-1358. https://doi.org/10.1016/j.jalz.2008.05.2452
  66. Rea R, Carotenuto A, Traini E, Fasanaro AM, Manzo V, Amenta F. Apathy Treatment in Alzheimer’s Disease: Interim Results of the ASCOMALVA Trial. Journal of Alzheimer’s Disease [Internet]. IOS Press. 2015;48(2):377-383. https://doi.org/10.3233/jad-141983
  67. Lanctôt KL, Herrmann N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry. 2000;15(4):338-345.
  68. Gauthier S, Juby A, Rehel B, Schecter R. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer’s disease. Int J Clin Pract. 2007;61(6):886-895. https://doi.org/10.1111/j.1742-1241.2007.01387.x
  69. Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease: results of a 52-week open-label study. Curr Med Res Opin. 2004;20(10):1605-1612. https://doi.org/10.1185/030079904125004204
  70. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry. 2000;15(5):387-392.
  71. Gauthier S, Juby A, Dalziel W, Réhel B, Schecter R. Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE). Current Medical Research and Opinion [Internet]. Informa Healthcare. 2010;26(5):1149-1160. https://doi.org/10.1185/03007991003688888
  72. Cummings JL, Koumaras B, Chen M, Mirski D; Rivastigmine Nursing Home Study Team. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005;3(3):137-148. https://doi.org/10.1016/s1543-5946(05)80020-0
  73. Potkin SG, Alva G, Gunay I, Koumaras B, Chen M, Mirski D. A Pilot Study Evaluating the Efficacy and Safety of Rivastigmine in Patients with Mixed Dementia. Drugs & Aging [Internet]. Springer Nature. 2006;23(3):241-249. https://doi.org/10.2165/00002512-200623030-00006
  74. Devos D, Moreau C, Maltête D, Lefaucheur R, Kreisler A, Eusebio A, Defer G, Ouk T, Azulay JP, Krystkowiak P, Witjas T, Delliaux M, Destée A, Duhamel A, Bordet R, Defebvre L, Dujardin K. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014;85(6):668-674. https://doi.org/10.1136/jnnp-2013-306439
  75. Oh YS, Kim JS, Lee PH. Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia. J Mov Disord. 2015;8(2):98-102. https://doi.org/10.14802/jmd.15041
  76. Moretti R. Rivastigmine in subcortical vascular dementia: A randomized, controlled, open 12-month study in 208 patients. American Journal of Alzheimer’s Disease and Other Dementias [Internet]. SAGE Publications. 2003;18(5):265-272. https://doi.org/10.1177/153331750301800508
  77. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in vascular dementia. Expert Opinion on Pharmacotherapy [Internet]. Informa Healthcare. 2004;5(6):1399-1410. https://doi.org/10.1517/14656566.5.6.1399
  78. Brodaty H, Woodward M, Boundy K, Barnes N. Naturalistic Treatment of Alzheimer's Disease with Galantamine. CNS Drugs [Internet]. Springer Nature. 2007;21(4):335-336. https://doi.org/10.2165/00023210-200721040-00006
  79. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1283-1290. https://doi.org/10.1016/s0140-6736(02)08267-3
  80. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer’s Disease. American Journal of Psychiatry [Internet]. American Psychiatric Publishing. 2004;161(3):532-538. https://doi.org/10.1176/appi.ajp.161.3.532
  81. Grimmer T, Kurz A. Effects of Cholinesterase Inhibitors on Behavioural Disturbances in Alzheimer’s Disease. Drugs & Aging [Internet]. Springer Nature. 2006;23(12):957-967. https://doi.org/10.2165/00002512-200623120-00003
  82. Kaufer D. Beyond the Cholinergic Hypothesis: The Effect of Metrifonate and Other Cholinesterase Inhibitors on Neuropsychiatric Symptoms in Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders [Internet]. S. Karger AG. 1998;9(2):8-14. https://doi.org/10.1159/000051193
  83. Dubois B, McKeith I, Orgogozo JM, Collins O, Meulien D. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer’s disease: the MALT study. Int J Geriatr Psychiatry. 1999;14(11):973-982.
  84. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20(5):459-464. https://doi.org/10.1002/gps.1341
  85. Diehl‐Schmid J, Förstl H, Perneczky R, Pohl C, Kurz A. A 6‐month, open‐label study of memantine in patients with frontotemporal dementia. International Journal of Geriatric Psychiatry [Internet]. Wiley-Blackwell. 2008;23(7):754-759. https://doi.org/10.1002/gps.1973
  86. Pantev M, Ritter R, Gortelmeyer R. Clinical and behavioural eveluation in long-term care patients with mild to modertae dementia under memantine treatment. Zeitschrt fur Gerontopsychologie Und-Psychiatrie. 1993;6:103-117.
  87. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333-1341. https://doi.org/10.1056/nejmoa013128
  88. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil. JAMA [Internet]. American Medical Association (AMA). 2004;291(3):317. https://doi.org/10.1001/jama.291.3.317
  89. Diehl‐Schmid J, Förstl H, Perneczky R, Pohl C, Kurz A. A 6‐month, open‐label study of memantine in patients with frontotemporal dementia. International Journal of Geriatric Psychiatry [Internet]. Wiley-Blackwell. 2008;23(7):754-759. https://doi.org/10.1002/gps.1973
  90. Swanberg MM. Memantine for Behavioral Disturbances in Frontotemporal Dementia. Alzheimer Disease & Associated Disorders [Internet]. Ovid Technologies (Wolters Kluwer Health). 2007;21(2):164-166. https://doi.org/10.1097/wad.0b013e318047df5d
  91. Kuronen M, Koponen H, Nykänen I, Karppi P, Hartikainen S. Use of anti-dementia drugs in home care and residential care and associations with neuropsychiatric symptoms: a cross-sectional study. BMC Geriatr. 2015;15:100. https://doi.org/10.1186/s12877-015-0102-4
  92. Rea R, Carotenuto A, Traini E, Fasanaro AM, Manzo V, Amenta F. Apathy Treatment in Alzheimer’s Disease: Interim Results of the ASCOMALVA Trial. Journal of Alzheimer’s Disease [Internet]. IOS Press. 2015;48(2):377-383. https://doi.org/10.3233/jad-141983
  93. Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, Lanctôt KL. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008;28(3):296-301. https://doi.org/10.1097/JCP.0b013e318172b479
  94. Kaplitz SE. Withdrawn, Apathetic Geriatric Patients Responsive to Methylphenidate. Journal of the American Geriatrics Society [Internet]. Wiley-Blackwell. 1975;23(6):271-276. https://doi.org/10.1111/j.1532-5415.1975.tb00317.x
  95. Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, et al. Methylphenidate for Apathy and Functional Status in Dementia of the Alzheimer Type. The American Journal of Geriatric Psychiatry [Internet]. Elsevier BV. 2010;18(4):371-374. https://doi.org/10.1097/jgp.0b013e3181cabcf6
  96. Frakey LL, Salloway S, Buelow M, Malloy P. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer’s disease. J Clin Psychiatry. 2012;73(6):796-801. https://doi.org/10.4088/JCP.10m06708
  97. Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, Bauer L. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease. BMC Neurol. 2016;16:90. https://doi.org/10.1186/s12883-016-0610-7
  98. Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, Schmid M, Singh P, Tolosa E, Chaudhuri KR. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms — results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22(10):1400-1407. https://doi.org/10.1111/ene.12757
  99. Blundo C, Gerace C. Dopamine agonists can improve pure apathy associated with lesions of the prefrontal-basal ganglia functional system. Neurol Sci. 2015;36(7):1197-1201. https://doi.org/10.1007/s10072-014-2061-5
  100. Van Reekum R, Bayley M, Garner S. amantadine for the amotivational syndrome in a patient with traumatic brain injury. Journal of Head Trauma Rehabilitation [Internet]. Ovid Technologies (Wolters Kluwer Health). 1995;10(6):90. https://doi.org/10.1097/00001199-199512000-00017
  101. Thobois S, Lhommée E, Klinger H, Ardouin C, Schmitt E, Bichon A, Kistner A, Castrioto A, Xie J, Fraix V, Pelissier P, Chabardes S, Mertens P, Quesada JL, Bosson JL, Pollak P, Broussolle E, Krack P. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;136(5):1568-1577. https://doi.org/10.1093/brain/awt067
  102. Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, Caglieris N, Sterlicchio M, Capurso A, Tomasi NA, et al. Nimodipine in the treatment of old age dementias. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(4):525-551. PubMed PMID: 2236581.
  103. Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D. A Preliminary Open Trial with Nimodipine in Patients with Cognitive Impairment and Leukoaraiosis. Clinical Neuropharmacology [Internet]. Ovid Technologies (Wolters Kluwer Health). 1996;19(6):497-506. https://doi.org/10.1097/00002826-199619060-00003
  104. Starkstein SE, Brockman S, Hatch KK, Bruce DG, Almeida OP, Davis WA, Robinson RG. A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy. J Stroke Cerebrovasc Dis. 2016;25(5):1119-1127. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.01.032
  105. European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol. 1996;36(5):315-321. PubMed PMID: 8864715.
  106. Sival RC, Judith Haffmans PM, Jansen PAF, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia?a randomized placebo controlled clinical trial. International Journal of Geriatric Psychiatry [Internet]. Wiley-Blackwell. 2002;17(6):579-585. https://doi.org/10.1002/gps.653
  107. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Gabapentin for the Treatment of Behavioural Alterations in Dementia. Drugs & Aging [Internet]. Springer Nature. 2003;20(14):1035-1040. https://doi.org/10.2165/00002512-200320140-00003
  108. Berman K, Brodaty H, Withall A, Seeher K. Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatry. 2012;20(2):104-122. https://doi.org/10.1097/JGP.0b013e31822001a6
  109. Cummings JL. Toward a molecular neuropsychiatry of neurodegenerative diseases. Annals of Neurology [Internet]. Wiley-Blackwell. 2003;54(2):147-154. https://doi.org/10.1002/ana.10616
  110. Overshott R, Byrne J, Burns A. Nonpharmacological and pharmacological interventions for symptoms in Alzheimer’s disease. Expert Review of Neurotherapeutics [Internet]. Informa Healthcare. 2004;4(5):809-821. https://doi.org/10.1586/14737175.4.5.809
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.